Journal: Data in Brief

Article Title: Multibeam bathymetry data from the Kane Gap and south-eastern part of the Canary Basin (Eastern tropical Atlantic)

doi: 10.1016/j.dib.2020.106055

Figure Lengend Snippet:

Article Snippet: Description of data collection , The raw multibeam data were processed using QINSy software (QPS, Netherlands). Validated multibeam data were converted into the ASCII-table (*.txt).The DEMs were created by triangle surface method and converted into ESRI ASCII grid (*.asc) and GeoTIFF raster (*.tif) in QINSy and ArcGIS software..

Techniques: Software

Journal: Data in Brief

Article Title: Multibeam bathymetry data from the Kane Gap and south-eastern part of the Canary Basin (Eastern tropical Atlantic)

doi: 10.1016/j.dib.2020.106055

Figure Lengend Snippet:

Article Snippet: Data format , Raw and analysed: Tabular data: ASCII table (*.txt), DEMs: ESRI ASCII grid (*.asc), GeoTIFF raster (*.tif).

Techniques: Software

Journal: Journal of Extracellular Vesicles

Article Title: Therapeutic potential of mesenchymal stem cell‐derived extracellular vesicles in SARS‐CoV‐2 and H1N1 influenza‐induced acute lung injury

doi: 10.1002/jev2.12495

Figure Lengend Snippet: Anti‐viral effects of ASC‐EVs against SARS‐CoV‐2. (a) The effects of ASC‐EVs on cell viability of Vero E6 cells. Vero E6 cells were treated with ASC‐EVs, and after 24 h a CCK‐8 assay was performed to determine the viability of the cells. (b) Plaque assay of SARS‐CoV‐2–induced cell death. Vero E6 cells were treated with SARS‐COV‐2 (10 3 TCID 50 /well) + ASC‐EVs (from 0.15 × 10 9 to 5.0 × 10 9 particles/mL) and the CPEs were evaluated from 72 h after infection. (c) The mean plaque reduction in Vero E6 cells with increasing concentrations of ASC‐EVs ( n = 3). (d) The relative expression of SARS‐CoV‐2–specific genes ( E , RdRP and N ) was measured using quantitative real‐time polymerase chain reaction (the top three figures show data for 10 1 TCID 50 , and the lower three figures show data for 10 2 TCID 50 . Data are presented as the mean ± standard deviation from three independent experiments; *** p < 0.001 and * p < 0.05 compared to SARS‐CoV‐2 (10 1 TCID 50 ) + ASC‐EVs; ### p < 0.001 compared to SARS‐CoV‐2 (10 2 TCID 50 ) + ASC‐EVs. (e) Body weight of Syrian hamsters exposed to SARS‐CoV‐2 infection with virus inoculated on day 0. All animals survived throughout the experiment ( n = 8). (f) Photograph of the Syrian hamster lungs 7 days after induction of SARS‐CoV‐2 infection. Fewer spots of bleeding and reduced overall redness were observed in animals treated with ASC‐EVs. (g) Micrographs of Syrian hamster lung sections at 5 or 7 days after the induction of SARS‐CoV‐2 infection. ASC‐EVs increased the area of apparent alveoli and reduced cellularity. The scale bar is 250 µm. DPI, days post‐infection. Magnification is 40× (first and third row) and 400× (second and fourth row).

Article Snippet: ASC‐EVs (ASCE™ is the proprietary trademark of ExoCoBio Inc.) were isolated from ASC‐CM using tangential flow filtration (TFF)‐based ExoSCRT™ technology as previously described (Lee et al., ).

Techniques: CCK-8 Assay, Plaque Assay, Infection, Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Virus

Journal: Journal of Extracellular Vesicles

Article Title: Therapeutic potential of mesenchymal stem cell‐derived extracellular vesicles in SARS‐CoV‐2 and H1N1 influenza‐induced acute lung injury

doi: 10.1002/jev2.12495

Figure Lengend Snippet: Anti‐viral effects of ASC‐EVs against H1N1 influenza A virus. (a) Kaplan–Meier survival plot for mice infected with H1N1 virus on day 0. Treatment with higher numbers of intravenous injections of ASC‐EVs reduced mortality (red curve). Mice that lost more than 20% of their body weight were sacrificed and recorded as death. Only a few mice in the ASC‐EV group survived after H1N1 infection in the experiment ( n = 11). (b) Body weight of mice infected with H1N1 virus on day 0. The mice that survived the infection beyond day 10 recovered their body weight (no statistical analysis was performed). (c) Body temperature up to day 8 in mice infected with H1N1 virus on day 0. Treatment with ASC‐EVs significantly reduced the drop in body temperature on day 6. (d) Clinical score up to day 14 in mice infected with H1N1 virus on day 0. Treatment with ASC‐EV four times intravenously significantly improved the clinical score. (e) Macroscopic photographs of mouse lungs post‐mortem after H1N1 virus infection on day 0 versus controls. The lungs of mice treated with vehicle appeared dark red with spots of bleeding, whereas the ASC‐EV treatment reduced this morphology. (f) Representative micrographs (H&E staining) of lungs from the different groups infected with the H1N1 virus and treated with ASC‐EVs. The scale bar is 250 µm. DPI, days post‐infection. (g) Post‐mortem histopathological scores of peribronchiolar, perivascular and parenchymal lung tissue in mice infected with H1N1 virus on day 0 and treated with vehicle or ASC‐EVs with two different treatment regimens. (h) Quantification of total inflammatory cells in H1N1‐infected mouse lung tissue.

Article Snippet: ASC‐EVs (ASCE™ is the proprietary trademark of ExoCoBio Inc.) were isolated from ASC‐CM using tangential flow filtration (TFF)‐based ExoSCRT™ technology as previously described (Lee et al., ).

Techniques: Virus, Infection, Staining

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Percentage of laboratories performing in-house ERBB2/HER2 (human epidermal growth factor receptor 2) testing in endometrial serous carcinoma and colorectal carcinoma.

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques:

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Percentage of laboratories performing ERBB2/HER2 testing in (A) endometrial serous carcinoma (ESC) and (B) colorectal carcinoma (CRC) as a function of location and institution type. The numbers of laboratories responding to the survey are shown at the right of each panel.

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques:

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Case Volume and Testing Practices for ERBB2 /HER2 (Human Epidermal Growth Factor Receptor 2) Testing in Endometrial Serous Carcinoma (ESC)

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques: Amplification, Selection

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Algorithm, Technique, and Reporting for ERBB2 /HER2 (Human Epidermal Growth Factor Receptor 2) Testing in Endometrial Serous Carcinoma (ESC)

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques:

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Case Volume and Testing Practices for ERBB2 /HER2 (Human Epidermal Growth Factor Receptor 2) Testing in Colorectal Carcinoma (CRC)

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques: Amplification, Selection

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Algorithm, Technique, and Reporting for ERBB2/HER2 (Human Epidermal Growth Factor Receptor 2) Testing in Colorectal Carcinoma (CRC)

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques:

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Summary of Published ERBB2 /HER2 (Human Epidermal Growth Factor Receptor 2) Immunohistochemistry (IHC) Guidelines Relevant to Breast and Colorectal Carcinoma

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques: Immunohistochemistry, Staining

Journal: Archives of pathology & laboratory medicine

Article Title: Current Laboratory Testing Practices for Assessment of ERBB2 /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma

doi: 10.5858/arpa.2022-0229-CP

Figure Lengend Snippet: Summary of Published ERBB2 /HER2 (Human Epidermal Growth Factor Receptor 2) Immunohistochemistry (IHC) Guidelines Relevant to Breast Cancer and Endometrial Serous Carcinoma

Article Snippet: No. (%) Laboratory requires the tumor to be RAS wild-type for ERBB2 /HER2 testing in CRC 234 Yes, required for all tumors 6 (2.6) Yes, required when RAS status is available 17 (7.3) No 211 (90.2) Algorithm used for ERBB2 /HER2 testing in CRC 237 IHC with reflex to ISH for equivocal results 195 (82.3) Both IHC and ISH testing 18 (7.6) ISH with reflex to IHC for equivocal results 5 (2.1) ISH only testing 4 (1.7) Other a 15 (6.3) Scoring criteria/guidelines used to report ERBB2 /HER2 IHC and ISH in CRC 233 CAP/ASCP/ASCO gastroesophageal adenocarcinoma HER2 guideline (PMID 27841667) 115 (49.4) The scoring system used in the HERACLES trial (PMID 26449765) 70 (30.0) ASCO/CAP 2018 guideline for breast carcinoma (PMID 29846122) 38 (16.3) Other b 10 (4.3) Open in a separate window Abbreviations: ASCO, American Society of Clinical Oncology; ASCP, American Society for Clinical Pathology; CAP, College of American Pathologists; IHC, immunohistochemistry; ISH, in situ hybridization. a Other responses: IHC only (7), clinician request (3), clinical trial requirement (1), ad hoc (1), HERACLES (1), and reflexively (1). b Other responses: original US Food and Drug Administration scoring criteria—HercepTest (2), positive versus negative (1), CAP 2013 breast guideline (1), based on ordering physician (1), and MyPathway (1).

Techniques: Immunohistochemistry, Staining

Journal: Tissue Engineering Part A

Article Title: Metabolically Active Three-Dimensional Brown Adipose Tissue Engineered from White Adipose-Derived Stem Cells

doi: 10.1089/ten.tea.2016.0399

Figure Lengend Snippet: Figure 1. Tissue culture methods. (A) ASCs isolated from rat BAT (bASCs) are

Article Snippet: Adipose-derived stem cell (ASC) isolation Rat ASCs were isolated from the subcutaneous WAT (wASCs) and interscapular BAT depots (bASCs) of female Sprague-Dawley rats.

Techniques: Isolation

Journal: Tissue Engineering Part A

Article Title: Metabolically Active Three-Dimensional Brown Adipose Tissue Engineered from White Adipose-Derived Stem Cells

doi: 10.1089/ten.tea.2016.0399

Figure Lengend Snippet: Figure 2. Differentiation of rat white and brown ASCs. (A) PPARγ, (B) UCP1

Article Snippet: Adipose-derived stem cell (ASC) isolation Rat ASCs were isolated from the subcutaneous WAT (wASCs) and interscapular BAT depots (bASCs) of female Sprague-Dawley rats.

Techniques:

Journal: Tissue Engineering Part A

Article Title: Metabolically Active Three-Dimensional Brown Adipose Tissue Engineered from White Adipose-Derived Stem Cells

doi: 10.1089/ten.tea.2016.0399

Figure Lengend Snippet: Figure 3. Differentiation of human white ASCs. (A) PPARγ, (B) UCP1

Article Snippet: Adipose-derived stem cell (ASC) isolation Rat ASCs were isolated from the subcutaneous WAT (wASCs) and interscapular BAT depots (bASCs) of female Sprague-Dawley rats.

Techniques: